Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.03-21

Century Therapeutics (NASDAQ:IPSC) Full Year 2024 Results

Key Financial Results

Net loss: US$126.6m (loss narrowed by 7.4% from FY 2023).
US$1.61 loss per share (improved from US$2.30 loss in FY 2023).

NasdaqGS:IPSC Earnings and Revenue Growth March 21st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Century Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) missed analyst estimates by 17%.

Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.

Performance of the American Biotechs industry.

The company's shares are down 1.5% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Century Therapeutics (2 are significant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521285358?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-21 19:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2521285358","market":"nz","top_or_hot":-1,"title":"Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","media":"Simply Wall St.","content":"<html><body><h2>Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NASDAQ:IPSC) Full Year 2024 Results</h2>\n<h3>Key Financial Results</h3>\n<ul>\n<li>Net loss: US$126.6m (loss narrowed by 7.4% from FY 2023).</li>\n<li>US$1.61 loss per share (improved from US$2.30 loss in FY 2023).</li>\n</ul>\n<figure>\n<img height=\"524\" src=\"https://s1.yimg.com/uu/api/res/1.2/GmFY6fKYa5ktrjo6SxFbxA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/simply_wall_st__316/37bc3d07ff628a3640b0c3532010be3e\" width=\"821\"/>\n<figcaption>\n  NasdaqGS:IPSC Earnings and Revenue Growth March 21st 2025\n </figcaption>\n</figure>\n<p><i>All figures shown in the chart above are for the trailing 12 month (TTM) period</i></p>\n<h3>Century Therapeutics Revenues Beat Expectations, EPS Falls Short</h3>\n<p> Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) missed analyst estimates by 17%. </p>\n<p> Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. </p>\n<p><i>Performance of the <strong>American Biotechs industry.</strong></i></p>\n<p> The company's shares are down 1.5% from a week ago. </p>\n<h3>Risk Analysis</h3>\n<p> Before you take the next step you should know about the <strong>4 warning signs for Century Therapeutics</strong> (2 are significant!) that we have uncovered. </p>\n<p><strong>Have feedback on this article? Concerned about the content?</strong> <strong>Get in touch</strong><strong> with us directly.</strong><i> Alternatively, email editorial-team (at) simplywallst.com.</i><br/><br/><i>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</i><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentury Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-21 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/century-therapeutics-full-2024-earnings-114333283.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Century Therapeutics (NASDAQ:IPSC) Full Year 2024 Results\nKey Financial Results\n\nNet loss: US$126.6m (loss narrowed by 7.4% from FY 2023).\nUS$1.61 loss per share (improved from US$2.30 loss in FY 2023...</p>\n\n<a href=\"https://finance.yahoo.com/news/century-therapeutics-full-2024-earnings-114333283.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPSC","symbol_name":"Century Therapeutics, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/century-therapeutics-full-2024-earnings-114333283.html","article_id":"2521285358","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521285358","pubTimestamp":1742557413,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGS:IPSC Earnings and Revenue Growth March 21st 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 97%. Earnings per share  missed analyst estimates by 17%.Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.The company's shares are down 1.5% from a week ago.Before you take the next step you should know about the 4 warning signs for Century Therapeutics (2 are significant!","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IPSC":"Century Therapeutics, Inc.","LENZ":"Therapeutics","CNBKA":"世纪银行"},"translate_title":"Century Therapeutics 2024年全年收益：收入超出预期，每股收益滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNBKA":1,"IPSC":1,"LENZ":1},"content_text":"Century Therapeutics (NASDAQ:IPSC) Full Year 2024 Results\nKey Financial Results\n\nNet loss: US$126.6m (loss narrowed by 7.4% from FY 2023).\nUS$1.61 loss per share (improved from US$2.30 loss in FY 2023).\n\n\n\n\n  NasdaqGS:IPSC Earnings and Revenue Growth March 21st 2025\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nCentury Therapeutics Revenues Beat Expectations, EPS Falls Short\n Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) missed analyst estimates by 17%. \n Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. \nPerformance of the American Biotechs industry.\n The company's shares are down 1.5% from a week ago. \nRisk Analysis\n Before you take the next step you should know about the 4 warning signs for Century Therapeutics (2 are significant!) that we have uncovered. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521285358"}